Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin

摘要

Cutaneous lymphomas account for 5% of non-Hodgkin lymphomas (NHLs). With 75% of skin lymphomas originating from T-cells, CD30+ anaplastic large-cell NHL (ALCL) is the second most common type after mycosis fungoides. In treatment, excision and radiotherapy are the first options for single lesions, but systemic treatment is required for multiple ones. Brentuximab vedotin (BV) is an antibody-drug conjugate composed of a CD30-directed monoclonal antibody and monomethyl auristatin E. Recently, it has been used in the treatment of Hodgkin lymphoma and chemotherapy-resistant ALCL [1,2,3].